Healio: A survey of patients with insomnia who participated in two phase 3 trials investigating daridorexant reported that “improved daytime functioning” was the most important treatment outcome for their condition.

The study was one of several abstracts on the oral sleep therapy daridorexant (Idorsia Pharmaceuticals) that were presented during the virtual SLEEP 2021 meeting.

Daridorexant is an orexin receptor 2 agonist that was developed for the treatment of insomnia. It is currently awaiting approval from the FDA, Emmanuel Mignot, MD, PhD, a professor of sleep medicine at Stanford University who has studied the drug, told Healio Primary Care.

“The orexin system keeps the brain awake, so it induces sleep differently from classical benzodiazepine‐acting sleeping pills such as zolpidem, which work by decreasing overall neuronal activity,” he said.

Get the full story at healio.com.